BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29616860)

  • 1. Targeting HAUSP in both p53 wildtype and p53-mutant tumors.
    Tavana O; Sun H; Gu W
    Cell Cycle; 2018; 17(7):823-828. PubMed ID: 29616860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HAUSP-nucleolin interaction is regulated by p53-Mdm2 complex in response to DNA damage response.
    Lim KH; Park JJ; Gu BH; Kim JO; Park SG; Baek KH
    Sci Rep; 2015 Aug; 5():12793. PubMed ID: 26238070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-B-associated transcript 3 (Bat3) stabilizes and activates p53 in a HAUSP-dependent manner.
    Zhang R; Cui D; Xue T; Lang Y; Zhang Y; Li L; Sun H; Kuang Y; Li G; Tang J
    J Mol Cell Biol; 2020 Feb; 12(2):99-112. PubMed ID: 31647545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells.
    Colland F; Formstecher E; Jacq X; Reverdy C; Planquette C; Conrath S; Trouplin V; Bianchi J; Aushev VN; Camonis J; Calabrese A; Borg-Capra C; Sippl W; Collura V; Boissy G; Rain JC; Guedat P; Delansorne R; Daviet L
    Mol Cancer Ther; 2009 Aug; 8(8):2286-95. PubMed ID: 19671755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dynamic role of HAUSP in the p53-Mdm2 pathway.
    Li M; Brooks CL; Kon N; Gu W
    Mol Cell; 2004 Mar; 13(6):879-86. PubMed ID: 15053880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the p53/MDM2 interplay by HAUSP inhibitors.
    Tavana O; Gu W
    J Mol Cell Biol; 2017 Feb; 9(1):45-52. PubMed ID: 27927749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.
    Hu M; Gu L; Li M; Jeffrey PD; Gu W; Shi Y
    PLoS Biol; 2006 Feb; 4(2):e27. PubMed ID: 16402859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model.
    Becker K; Marchenko ND; Palacios G; Moll UM
    Cell Cycle; 2008 May; 7(9):1205-13. PubMed ID: 18418047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
    Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
    Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of HAUSP in vivo modulates p53 function.
    Kon N; Kobayashi Y; Li M; Brooks CL; Ludwig T; Gu W
    Oncogene; 2010 Mar; 29(9):1270-9. PubMed ID: 19946331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy.
    Harakandi C; Nininahazwe L; Xu H; Liu B; He C; Zheng YC; Zhang H
    Bioorg Chem; 2021 Nov; 116():105273. PubMed ID: 34474304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
    Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
    Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
    Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
    Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma.
    Tavana O; Li D; Dai C; Lopez G; Banerjee D; Kon N; Chen C; Califano A; Yamashiro DJ; Sun H; Gu W
    Nat Med; 2016 Oct; 22(10):1180-1186. PubMed ID: 27618649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HAUSP is required for p53 destabilization.
    Cummins JM; Vogelstein B
    Cell Cycle; 2004 Jun; 3(6):689-92. PubMed ID: 15118411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity.
    He Y; Li W; Lv D; Zhang X; Zhang X; Ortiz YT; Budamagunta V; Campisi J; Zheng G; Zhou D
    Aging Cell; 2020 Mar; 19(3):e13117. PubMed ID: 32064756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.
    Chen C; Song J; Wang J; Xu C; Chen C; Gu W; Sun H; Wen X
    Bioorg Med Chem Lett; 2017 Feb; 27(4):845-849. PubMed ID: 28108249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.